Synergy CHC initiated with a Buy at Roth MKM

Roth MKM analyst Sean McGowan initiated coverage of Synergy CHC (SNYR) with a Buy rating and $10 price target In 2023, the company had successfully trialed Focus Factor RTD beverage in Costco-Texas, and more recently, it had a trial run in Costco-Canada with similarly encouraging results, the analyst tells investors in a research note. Roth contends that the combination of growth in Focus Factor Original and the launch this quarter of Focus Factor RTD will produce strong revenue and Adjusted EBITDA growth.